Sir,

I read with interest, the letter to editor published in Lung India Jan-March issue on thrombocytopenia due to rifampicin by Dixit *et al*.\[[@ref1]\] The authors claim that only few cases of thrombocytopenia due to rifampicin in daily doses have been reported. Perhaps the authors have not searched the literature well. The disorder is not so rare.

Way back in 1985, I along with others (Sharma *et al*.\[[@ref2]\] ) have reported such a case of thrombocytopenia due to rifampicin in daily dose, with severe bleeding diathesis. Other reports of more than 20 cases are available on "PubMed." Many more may not have been reported since its occurrence is known for so many years. Most such cases have occurred in situations, where patients have been irregular on therapy or there are interruptions in rifampicin therapy, for one or the other reason.

Need not to emphasize that a high index of suspicion is warranted to unravel the disorder early and managed by prompt withdrawal of the drug. Patients who are irregular on therapy must be warned of reporting immediately, if they notice bleeding from any site.

Although Bhasin *et al*.\[[@ref3]\] have suggested that resumption of the drug is possible in these patients; in my opinion, it is best avoided looking to the serious nature of the reaction.
